Serum Neurofilament Levels and PML Risk in Patients With Multiple Sclerosis Treated With Natalizumab

Overview of attention for article published in Neurology: Neuroimmunology and Neuroinflammation, April 2021

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (92nd percentile)
Above-average Attention Score compared to outputs of the same age and source (53rd percentile)

Mentioned by

news: 1 news outlet

twitter: 30 X users

Readers on

mendeley: 41 Mendeley

So far, Altmetric has seen 33 X posts from 30 X users, with an upper bound of 144,025 followers.

RT @neurochecklists: "Serum NFL levels can identify natalizumab-treated patients with MS who will develop PML with a sensitivity of 67% and…

RT @XtineLebrunF: Serum Neurofilament Levels and PML Risk in Patients With Multiple Sclerosis Treated With Natalizumab https://t.co/p5ONu7Z…

@vallhebron & @cemcat_em colleagues bring us a Class I evidence study about serum NFL levels as a predictor of PML risk in #MultipleSclerosis patients receiving Natalizumab (Tysabri). 👇 https://t.co/0KzedimSQe

RT @XtineLebrunF: Serum Neurofilament Levels and PML Risk in Patients With Multiple Sclerosis Treated With Natalizumab https://t.co/p5ONu7Z…

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 29 additional X posts.